Do you want to read an article? Please log in or register.
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Central Nervous System Tumors
Related content
Genitourinary Cancer
Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma
Anticancer Res.
Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M
doi: 10.21873/anticanres.11480
Lung, Respiratory and Thoracic Cancer
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Arch Pathol Lab Med.
Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y
doi: 10.5858/arpa.2017-0388-CP.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Cancer Res
Zhu L, Chen Z, Zang H, Fan S, Gu J, Zhang G, Sun KD, Wang Q, He Y, Owonikoko TK, Ramalingam SS, Sun SY
doi: 10.1158/0008-5472.CAN-21-0556
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Cancer Res
Zhu L, Chen Z, Zang H, Fan S, Gu J, Zhang G, Sun KD, Wang Q, He Y, Owonikoko TK, Ramalingam SS, Sun SY
doi: 10.1158/0008-5472.CAN-21-0556
Gastrointestinal Cancer
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'
Eur J Cancer.
Schöffski P, Mir O, Kasper B, Papai Z, Blay JY, Italiano A, Benson C, Kopeckova K, Ali N, Dileo P, LeCesne A, Menge F, Cousin S, Wardelmann E, Wozniak A, Marreaud S, Litiere S, Zaffaroni F, Nzokirantevye A, Vanden Bempt I, Gelderblom H
doi: 10.1016/j.ejca.2020.04.021.
Skin Cancer
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
Melanoma Res.
Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R
doi: 10.1097/
Lung, Respiratory and Thoracic Cancer
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Drug Saf.
Rocco D, Battiloro C, Della Gravara L, Gridelli C
doi: 10.1007/s40264-018-0771-y.
Radio-Oncology
Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?
Semin Cancer Biol.
Prêtre V, Wicki A
doi: 10.1016/
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors
Cancer Treat Rev.
Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E
doi: 10.1016/j.ctrv.2017.06.001.